How to Induce Insulin Resistance In Vitro

Four protocols, four mechanisms, four different things to report.

Four protocols

ProtocolWorking concentrationDurationMechanismReversibility
Chronic insulin100 nM, serum-free or low-serum16–24 hIR/IRS-1 downregulation24–48 h after withdrawal
Palmitate100–400 µM, BSA-conjugated, 6:1 molar16–24 hDAG–PKCθ, ceramide, ER stressSlow, incomplete
CytokineTNF-α 10 ng/mL, or 50% macrophage-conditioned medium24 hSOCS induction, phosphatase activationPartial
High glucose25–30 mM48–72 hHexosamine flux, osmotic and methylglyoxal stressSlow; partly selection

Each produces a different molecular state. Reporting "we induced insulin resistance with palmitate" and "we induced it with insulin" as the same manipulation is the most common source of non-reproducibility in this literature.

Important distinction. The chronic insulin protocol is desensitisation. It is the easiest to perform, the most reversible, and the least representative of human insulin resistance, in which signalling is impaired at normal receptor density.

Palmitate: the concentration is not the concentration

Palmitate is insoluble and is delivered bound to fatty-acid-free BSA. The biologically relevant quantity is the free fatty acid concentration, which depends on the molar ratio of fatty acid to albumin, not on the nominal concentration added.

ParameterPractical valueWhy
BSAFatty-acid-free, ≥ 98%Residual fatty acids in normal BSA dominate at low palmitate
Molar ratio3:1 to 6:1 (FA:BSA)Higher ratios give higher free concentration and more precipitation
ConjugationDissolve palmitate in ethanol or NaOH at 70 °C, then add to BSA solution at 37 °CDirect addition to medium precipitates
Filtration0.22 µm after conjugationRemoves crystals that otherwise act as phagocytic particles
Vehicle controlBSA at the same molar concentrationBSA alone alters lipid availability and signalling

Caveat on the vehicle. BSA binds and delivers lipids from serum, and it adsorbs to surfaces. A BSA-only control is not a null control; it is a low-level lipid exposure. The correct comparison is BSA-matched, and the difference between BSA and no-BSA is itself an effect.

The readout: a dose–response, not a single point

  1. Serum-starve 4–6 h (not overnight — overnight starvation itself reduces insulin signalling).
  2. Stimulate with insulin at 0, 0.1, 1, 10, 100 nM for 10 min at 37 °C.
  3. Lyse directly in hot SDS buffer; phosphatases are fast and cold lysis is not fast enough for some sites.
  4. Blot for p-AKT T308, p-AKT S473, total AKT, and the upstream node that the model is supposed to affect (IRS-1, IRβ).
  5. Fit the dose–response and report EC₅₀ and maximum, not a fold-change at one concentration.
ResultInterpretationFollow-up
Right shift, same maximumReduced sensitivityReceptor-proximal mechanism; check IRS-1/IR
Lower maximum, same EC₅₀Reduced capacityCheck GLUT4 content, signalling machinery abundance
BothMixedReport both parameters

Readout note. A single 10 nM point cannot separate these. At 10 nM, a right-shifted curve and a flattened curve both give a reduced signal, and the two imply different targets.

Functional confirmation

Signalling is a proxy. The functional readouts differ by cell type:

Cell typeFunctional readoutNote
Myotube2-DG uptake ± insulin; glycogen2-DG is not linear with transport rate
Adipocyte2-DG uptake; glycerol release ± isoproterenolLipolysis suppression is insulin action too
HepatocyteGlucose output; de novo lipogenesisMeasure both — hepatic resistance is selective

Important distinction. In hepatocytes, the two arms diverge: glucose output becomes resistant while lipogenesis remains insulin-sensitive or increases. A protocol that reduces p-AKT uniformly has produced a state that does not match the human hepatic phenotype, and reporting only glucose output will hide it.

Controls that are usually missing

  • • Osmotic control for high glucose: 25 mM mannitol or L-glucose.
  • • Vehicle-matched BSA for palmitate.
  • • Time-matched, insulin-free control for the chronic insulin protocol — the cells have been in culture the same number of days.
  • • Washout arm to establish reversibility, which distinguishes desensitisation from toxicity.
  • • Viability at the end: palmitate at 400 µM kills cells in some lines, and dead cells do not signal.
  • • Confluence and passage recorded: both change basal and stimulated uptake.

Reporting checklist

Six items make the experiment reproducible:

  1. Cell type, passage, and confluence at treatment.
  2. Serum concentration during treatment and during starvation.
  3. Inducer, concentration, vehicle, and duration.
  4. Insulin concentrations used and stimulation time.
  5. The phosphorylation sites blotted, with total-protein controls.
  6. EC₅₀ and maximum for the dose–response, with n and replicate definition.

Failures that recur

  • • 100 nM insulin used as "stimulation" rather than as the induction protocol. At that concentration, sensitivity differences saturate.
  • • Overnight starvation. It reduces insulin signalling by itself.
  • • Palmitate added directly to medium. It precipitates.
  • • No BSA control. The vehicle is a treatment.
  • • Total GLUT4 blotted to assess translocation. Total is usually unchanged.
  • • p-AKT S473 only. mTORC2-dependent and confounded by any mTOR effect.

Where this connects

  • • Insulin resistance models article supplies the interpretation layer: which of the three states each protocol produces.
  • • Lipid pillar supplies the palmitate handling rules, including the BSA ratio.
  • • Disease pillar supplies the tissue frame: the same protocol means different things in myotube, adipocyte and hepatocyte.

Scientific interpretation and experimental design

  • • Name the mechanism, not just the inducer. Desensitisation, lipid interference and cytokine signalling are different.
  • • Report the free fatty acid ratio. Nominal concentration is not exposure.
  • • Run a dose–response. EC₅₀ and maximum are the result.
  • • Include a washout arm. Reversibility distinguishes adaptation from injury.
  • • Match the functional readout to the cell type.
  • • Measure both hepatic arms. Resistance is selective.

Selected references for further reading

  • • Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiological Reviews. 2018;98:2133–2223.
  • • Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440:944–948.
  • • Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576:51–60.
  • • Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381–405.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: